聯系方式

電子郵箱：wangjj87@mail.sysu.edu.cn

辦公地址：中國廣州大學城外環東路132号太阳集团1088vip429室，郵編：510006

 

簡單介紹

王軍艦 博士，太阳集团1088vip教授、博士生導師，廣東省成藥性評估及評價工程實驗室副主任，廣東省粵港澳研究團隊帶頭人，廣東省傑出青年基金獲得者，中山大學“百人計劃二期”青年傑出人才。主要從事腫瘤藥理學和抗腫瘤創新藥物研究工作，緻力于發現和确證可藥性腫瘤治療新靶點，研發抗腫瘤創新藥物，探索腫瘤耐藥性和轉移作用機制，為癌症治療提供新策略。在 Nature Medicine, Cell Rep Med，Embo mol Med, J Am Chem Soc，Mol Ther等國際專業權威期刊發表研究性論文70餘篇。獲授權專利8項。獲得2016年國際前列腺癌基金會Challenge Award。兼任 Cell Biology International 雜志副主編（Associate Editor）、《藥學學報》及 Acta Pharmaceutica Sinica B 青年編委、廣東省藥理學會理事、廣東省藥理學會海洋藥物藥理專業委員會（籌）主任委員、藥物篩選與評價專業委員會 & 抗炎免疫專業委員會副主任委員、中國藥理學會腫瘤藥理專業委員會委員。

 

招生招聘信息

  1. 課題組長期招聘具有藥理學、腫瘤學、神經生物學、免疫學、化學生物學或分子細胞生物學背景，對腫瘤藥理學和抗腫瘤創新藥物研發感興趣的博士後和專職研究員，課題組将提供額外每年5-10萬津貼。

 

研究方向

1. 腫瘤治療可藥性新靶點及先導藥物發現

2. 癌細胞與神經、免疫細胞互作調控機制

3. 腫瘤耐藥、轉移驅動機制

 

教育經曆

2006年9月至2009年6月 博士 中國科學院廣州生物醫藥與健康研究院

2007年8月至2007年10月 MERIT Student 香港中文大學

2002年9月至2005年6月 碩士 中山大學

1998年9月至2002年6月 學士 内蒙古大學

 

工作經曆

2017年9月 至今 教授 太阳集团1088vip

2014年9月 至 2017年8月 助理科學家 美國加利福尼亞大學戴維斯分校

2010年5月 至 2014年8月 博士後 美國加利福尼亞大學戴維斯分校

2009年7月 至 2009年12月 助理研究員 中國科學院廣州生物醫藥與健康研究院

2005年7月 至 2006年8月 研究助理 中國科學院廣州生物醫藥與健康研究院

 

社會/學術任職

Cell Biology International（Wiley），副主編

Acta Pharmaceutica Sinica B及《藥學學報》，青年編委 

美國癌症協會（AACR），會員   

國家自然科學基金函評專家 

中國藥理學會表觀遺傳藥理專業委員會，委員

中國藥理學會抗炎免疫藥理專業委員會，委員

中國抗癌協會抗癌藥物專業委員會，委員

廣東省藥理學會藥物篩選與評價專業委員會，副主任委員

廣東省藥理學會抗炎免疫藥理專業委員會，副主任委員

廣東省藥理學會，理事

 

承擔縱向科研項目

1. 國家自然科學基金面上項目，2023.01-2026.12，項目負責人 ，52萬元，在研

2. 廣東省自然科學基金粵穗聯合-粵港澳團隊項目，2023.10-2026.09，項目負責人，200萬元，在研

3. 廣東省科技計劃項目-粵港澳聯合創新領域項目，2023.01-2024.12，項目負責人，100萬元，在研

4. 中山大學高校基本科研業務費學科交叉團隊項目，2024.01-2026.12，項目負責人，50萬元，在研

5. 廣州醫科大學附屬第六醫院開放課題-重點項目，2023.02-2027.01，項目負責人，50萬元，在研

6. 國家自然科學基金面上項目，2019.01-2022.12，項目負責人 ，57萬元，結題

7. 廣東省傑出青年基金項目，2019.10-2023.09，項目負責人，100萬元，結題

8. 廣州市民生科技攻關項目，2020.03-2023.02，合作方負責人，結題

 

論著專利

代表性論文

  1. Junjian Wang, June X. Zou, Xiaoqian Xue, Demin Cai1, Yan Zhang, Zhijian Duan, Qiuping Xiang, Joy C. Yang, Maggie C. Louie, Alexander D. Borowsky, Allen C. Gao, Christopher P. Evans, Kit S. Lam, Jianzhen Xu, Hsing-Jien Kung, Ronald M. Evans, Yong Xu, and Hong-Wu Chen. 2016 ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nature Medicine. 22(5):488-96 doi:10.1038/nm.4070. (This paper is highlighted in NATURE, 532, 9, 2016 and NATURE REVIEWS UROLOGY, 13, 237, 2016)
  2. Jianwei Zheng#, Qianqian Wang#, Jianghe Chen, Guodi Cai, Zhenhua Zhang, Hongye Zou, June X Zou, Qianqian Liu, Hong Li, Sheng Li, Hong-Wu Chen, LinLin Lu, Yangiu Yuan*, Peiging Liu*, Juniian Wang*. 2024 Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor RORy represents an effective therapeutic opportunity in osteosarcoma, Cell Rep Med. 2024. Apr 24:101519
  3. Hong Wang, Huizi Sun, Jie Huang, Zhenhua Zhang, Guodi Cai, Chaofan Wang, Kai Xiao, Xiaofeng Xiong, Jian Zhang, Peiqing Liu, Xiaoyun Lu*, Weineng Feng*, Junjian Wang*. 2024, Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer, EMBO Molecular Medicine, 2024. Sep; 16(9):2043-2059.
  4. Qianqian Liu#, Junhua Wang#, Huizi Sun, Zhenhua Zhang, Hong Wang, Shuai Ma, Chenxi Zhang, Qianqian Wang, Guodi Cai, Jianwei zheng, Yichu Nie*, Peiqing Liu*, Junjian Wang*. 2024 Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma, Molecular Therapy, 2024 Mar 6;32(3):749-765. doi: 10.1016/j.ymthe.2024.01.032.
  5. Xiaolu Wang, Qianqian Wang, Hong Wang, Guodi Cai, Yana An, peiqing liu, Huihao Zhou, Hongwu Chen, Shufeng Ji*, Jiantao Ye*, Junjian Wang*. 2024 Small protein ERSP encoded by LINC02870 promotes triple negative breast cancer progression via IRE1α/XBP1s activation, Cell Death and Differentiation, 2024, Accept.

近年其他通訊或一作論文

  1. Jie Huang, Shi-Ling Zhang, Chao Zhang, Weiye Huang, Zhenhua Zhang, Yu-Qing Chen, Jun-Wei Su, Hong-Hong Yan, Hua-Jun Chen, Jin-Ji Yang, Junjian Wang*, Yi-Long Wu*. 2024 Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation, Clin Transl Med, 2024 May;14(5):e1683. doi: 10.1002/ctm2.1683.
  2. Hong Wang, Qianqian Wang, Guodi Cai, Zhijian Duan, Zoann Nugent, Jie Huang, Jianwei Zheng, Alexander D. Borowsky, Jian Jian Li, Peiqing Liu, Hsing-Jien Kung, Leigh Murphy, Hong-Wu Chen*, Junjian Wang*. 2022 Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop via Nrf2 in cancer therapeutic resistance, Acta Pharmaceutica Sinica B, 12(4): 1871-1884.
  3. Shaoqiang Guo, Miaomiao Miao, Yufeng Wu, Qinyan Wu, Dongyue Pan, Zhanfang Kang, Jianwen Zeng, Chengfei Liu*, Guoping Zhong*, Junjian Wang*, 2024 DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer, Oncogene. 2024 May;43(19):1399-1410.
  4. Chenxi Zhang#, Xiaojuan Wang#, Guodi Cai, Hong Wang, Qianqian Liu, Shuai Ma, Huizi Sun, Yana An, Miaomiao Miao, Sheng Yin, Peiqing Liu, Xiaolu Wang*, Junjian Wang*. 2024 Targeting KPNB1 with genkwadaphnin suppresses gastric cancer progression through the Nur77-mediated signaling pathway. Eur J Pharmacol. 2024 May 30:176697.
  5. Wei Fang, Jianwei Zheng, Lin Deng, Yana An, Deqin Rong, Jianwei Wei, Xiao-Feng Xiong, Junjian Wang*, Yuanxiang Wang*. 2024 Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer, J Med Chem. 2024 Jan 25;67(2):1481-1499.
  6. Jia-Luo Huang, Xue-Long Yan, Dong Huang, Lu Gan, Huahua Gao, Run-Zhu Fan, Shen Li, Fang-Yu Yuan, Xinying Zhu, Gui-Hua Tang, Hong-Wu Chen, Junjian Wang*, Sheng Yin*, Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer, Acta Pharmaceutica Sinica B, 2023, 2023 Dec;13(12):4934-4944.
  7. Zongbo Feng, Chunju Yang, Yi Zhang, Huaxuan Li, Wei Fang, Junhua Wang, Yichu Nie, Chang-Yun Wang, Zhiqing Liu, Zhimin Jiang, Junjian Wang*, Yuanxiang Wang*.2023, Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.  J Med Chem. 2023 Jun 2. doi: 10.1021/acs.jmedchem.3c0041.
  8. Jia-Luo Huang, Xue-Long Yan, Wei Li, Run-Zhu Fan, Shen Li, Jianghe Chen, Zhenhua Zhang, Jun Sang, Lu Gan, Gui-Hua Tang, Hongwu Chen, Junjian Wang*, Sheng Yin*. 2022 Discovery of Highly Potent Daphnane Diterpenoids Uncovers Importin-β1 as a Druggable Vulnerability in Castration-Resistant Prostate Cancer, J Am Chem Soc, 2022 Sep 14. doi: 10.1021/jacs.2c06449
  9. Jianghe Chen, Yiwei Hu, Jian Zhang, Qianyu Wang, Xiongzhi Wu, Weiye Huang, Qianqian Wang, Guodi Cai, Hong Wang, Tianmiao Ou, Weineng Feng, Peiqing Liu, Yonghong Liu, Junfeng Wang, Jie Huang, Junjian Wang*. 2022, Therapeutic targeting RORγ with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate. Pharmacol Res. 2022, Mar 5;106160.
  10. Lin Zhong, Bin Yang, Zhenhua zhang, Junfeng Wang, Xiaojuan Wang, Yinfeng Guo, Weifeng Huang, Qianqian Wang, Guodi Cai, Fan Xia, Shengning Zhou, Shuai Ma, Yichu Nie, Jinping Lei, Min Li, Peiqing Liu, Wenbin Deng, Yonghong Liu, Fanghai Han*, Junjian Wang*. Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer. cell death & disease. 2022 Feb 18;13(2):161.
  11. Xiaowei Luo*, Guodi Cai, Yinfeng Guo, Chenghai Gao, Weifeng Huang, Zhenhua Zhang, Humu Lu, Kai Liu, Jianghe Chen, Xiaofeng Xiong, Jinping Lei, Xuefeng Zhou*, Junjian Wang*, Yonghong Liu*. 2021 Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 64(18):13918-13932. (Supplementary Journal Cover)
  12. Hong Wang, Zhe Chang, Guo-di Cai, Ping Yang, Jiang-he Chen, Shan-shu Yang, Yin-feng Guo, Ming-yu Wang, Xue-hua Zheng, Jin-ping Lei, Pei-qing Liu, De-peng Zhao* & Jun-jian Wang*，2021 The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants. Acta Pharmacol Sin., 2021 Jul 28 doi: 10.1038/s41401-021-00738-w
  13. Liu-shan Chen, Meng Zhang, Peng Chen, Xiao-feng Xiong, Pei-qing Liu, Hai-bin Wang, Jun-jian Wang* & Juan Shen*. 2021 The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2021 Aug 30. doi: 10.1038/s41401-021-00756-8. 
  14. Yuhui Xie, Lang Guo, Jie Huang, Xiaolong Huang, Ziwen Cong, Qianqian Liu, Qianshu Wang, Xiaoyan Pang, Songtao Xiang, Xuefeng Zhou, Liu Yonghong*, Wang Junjian*, Wang Junfeng*. Cyclopentenone-Containing Tetrahydroquinoline and Geldanamycin Alkaloids from Streptomyces malaysiensis as Potential Anti-Androgens against Prostate Cancer Cells. J Nat Prod. 2021 Jul 6. doi: 10.1021/acs.jnatprod.1c00297.
  15. Zhenhua Zhang, Yidi Zhang, Chunju Yang, Qianyu Wang, Hong Wang, Yanting Zhang, Wenbin Deng, Yichu Nie, Yonghong Liu, Xiaowei Luo*, Jie Huang*, Junjian Wang*. 2021 Antitumor effects of 3-bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway. Cell Biol Int. 2021 Jul 21. doi: 10.1002/cbin.11674.
  16. Su Zhou, Qianqian Liu, Ming Bao, Jie Huang*, Junjian Wang*, Wenhao Hu and Xinfang Xu*. Gold(i)-catalyzed redox transformation of o-nitroalkynes with indoles for the synthesis of 2,3′-biindole derivatives. Org. Chem. Front., 2021,8,1808.DOI: 10.1039/d1qo00134e 
  17. Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xaiolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu*, Fanghai Han*, Junjian Wang*. 2020 Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin, Acta Pharmaceutica Sinica B, 10(12), 2313-2322 
  18. Qianqian Wang, Jianwei Zheng, June X. Zou, Jianzhen Xu, Fanghai Han, Songtao Xiang, Peiqing Liu, Hong-Wu Chen*, Junjian Wang*. 2020, S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis. Chem Biol Interact. 2020 Jan 27:108965. doi: 10.1016/j.cbi.2020.108965.
  19. Wei-Hao Chen, Kun-Long Li, Xiu-Ping Lin, Sheng-Rong Liao, Bin Yang, Xue-Feng Zhou, Jun-Jian Wang*, Yong-Hong Liu*, and Jun-Feng Wang*. 2020, Antioxidant CPA-type indole alkaloids produced from the deep-sea derived fungus Aspergillus sp. SCSIO41024. Natural Product Research. 2020 Apr 7:1-5. doi: 10.1080/14786419.2020.1749614.
  20. Menghan Gao, Lang Guo, Hong Wang, Jialuo Huang, Fanghai Han, Songtao Xiang*, Junjian Wang*. 2020, Orphan Nuclear Receptor RORγ Confers Doxorubicin Resistance in Prostate Cancer. Cell Biology International, 44(10):2170-2176. doi: 10.1002/cbin.11411.
  21. Jing Lu, Jingyan Li, Yuehuai Hu, Dayue Darrel Duan, Zhen Guo, Duanping Sun, Panxia Wang, Kaiteng Guo, Si Gao, Jianmin Jiang, Junjian Wang*, Peiqing Liu*, 2019 Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation, Acta Pharmaceutica Sinica B, 9(4): 782-793.
  22. Junjian Wang, June X. Zou, Hong Wang, Zhijian Duan, Haibin Wang, Peng Chen, Peiqing Liu, Jianzhen Xu, Hong-Wu Chen, 2019, Histone methyltransferase NSD2 mediates survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling, Acta Pharmacol Sin. 2019 40(8):1067-1075.
  23. Xiao‐Wei Luo, Cheng‐Hai Gao, Fang‐Hai Han, Xian‐Qiang Chen, Xiu‐Ping Lin, Xue‐Feng Zhou, Jun‐Jian Wang*, Yong‐Hong Liu*. 2019, A new naphthopyranone from the sponge‐associated fungus Penicillium sp. XWS02F62. Magnetic Resonance in Chemistry. https://doi.org/10.1002/mrc.4930
  24. Jing Yuan, Huiqi Hong, Yuhong Zhang, Jing Lu, Youhui Yu, Xueying Bi, Junjian Wang*, Jiantao Ye*, 2019, Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy through inhibiting JAK2/STAT3 signaling pathway. Cell Biology International, doi: 10.1002/cbin.11146. 
  25. Junjian Wang, Haibin Wang, Lingyu Wang, Demin Cai, Zhijian Duan, Yanhong Zhang, Peng Chen, June X. Zou, Jianzhen Xu, Xinbin Chen, Hsing-Jien Kung, Hong-Wu Chen. 2016 Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death&Differentiation. doi: 10.1038/cdd.2016.92.                                                 
  26. Junjian Wang, Zhijian Duan, Zoann Nugent, June X. Zou, Alexander D. Borowsky, Yanhong Zhang, Clifford G. Tepper, Jian Jian Li, Oliver Fienh, Jianzhen Xu, Leigh Murphy, Hsing-Jien Kung and Hong-Wu Chen. 2016 Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Letters. 378(2):69-79. doi: 10.1016/j.canlet.2016.05.004.                                                                                                                                       合作論文代表
  27. Jiao-jiao Yu, Dan-dan Zhou, Xiao-xiao Yang, Bing Cui, Fengwei Tan, Junjian Wang, Ke Li, Shuang Shang, Cheng Zhang, Xiao-xi Lv, Xiao-wei Zhang, Shan-shan Liu, Jin-mei Yu, Feng Wang, Bo Huang, Fang Hua, and Zhuowei Hu. 2020, TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. Nature Communications. 2020 Jul 21;11(1):3660. doi: 10.1038/s41467-020-17385-0
  28. Demin Cai, Junjian Wang, Bei Gao, Jin Li, Feng Wu, June X. Zou, Jianzhen Xu, Yuqian Jiang, Hongye Zou, Zenghong Huang, Alexander D. Borowsky, Richard J. Bold, Primo N. Lara, Jian Jian Li, Xinbin Chen, Kit S. Lam, Ka-Fai To, Hsing-Jien Kung, Oliver Fiehn, Ruqian Zhao, Ronald M. Evans & Hong-Wu Chen. 2019 RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nature Communications, OCT 11; 10(1): 4621. 

 

備注 * Corresponding author

所有發表論文

ORCID：https://orcid.org/0000-0002-5328-2908

專利

  1. 4-羟基-2-吡啶酮生物堿在制備治療胃癌藥物中的應用；專利申請号：202310074792.6；王軍艦,張晨曦,王紅,蔡國弟,王曉璐；授權有效（20240126-20440125）
  2. 一種吲哚類化合物及其合成方法和應用；專利号：ZL201910519513.6；趙德鵬，王軍艦，常喆，王紅；授權有效（2021.10.01-2041.09.30）。
  3. 一種G9a/GLP共價抑制劑及其制備方法及應用；專利号：CN202210738401.1；王元相, 王軍艦，馮宗博，楊春菊，劉培慶；授權有效（20230929-20420928）
  4. 一種雙吡啶甲酸酯類衍生物及其應用；專利申請号：2024106407481； 王軍艦，安亞娜，錢宇，趙磊，劉培慶；在審（申請日：20240522）
  5. 蛋白降解靶向嵌合體及其應用；專利申請号：202310314324.1；   陸小雲,王軍艦,王超凡,王紅；在審（申請日：20230328）

獲獎情況

2016 前列腺癌基金會Challenge Award